Namenda
Semantic Dementia
University of California, San FranciscoPhase 4 / ApprovedDormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Semantic Dementia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
FLUDEOXYGLUCOSE Mayo Clinic | Phase 1 | CC |
PITTSBURGH COMPOUND B UNLABELLED Mayo Clinic | Phase 1 | CC |
Verdiperstat Peter Ljubenkov, MD | Phase 1 | CC |
FLORTAUCIPIR Mayo Clinic | D | |
ER-176 Mayo Clinic | D |
Same molecule, other indications
Namenda is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →